Know the Latest About COVID-19 Monoclonal Antibodies

August 2021

Recent evidence and rising cases will renew focus on COVID-19 monoclonal antibodies...casirivimab/imdevimab (Regen-COV), etc.

Patients. Early data now suggest casirivimab/imdevimab reduces mortality in patients HOSPITALIZED due to COVID-19.

But it's not authorized for these patients yet...and the dose showing benefit is over 6 times the current authorized dose.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote